https://charts.traderzeitung.de/phases/US1711262048 string(1404) "{"isin":"US1711262048","name":"Pelthos Therapeutics Inc","stock_id_xnas":132475153,"stock_id_xnys":132475154,"generated_at":"2026-09-24 01:32:00","days":[{"date":"2026-09-21","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":22.81,"close_at":"2026-09-21 21:50:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-22","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":23.2,"close_at":"2026-09-22 21:40:00","complete":true,"perf_pct":1.7098},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-09-23","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":23.78,"close_at":"2026-09-23 21:25:00","complete":true,"perf_pct":2.5},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"

Pelthos Therapeutics Aktie News & Nachrichten

[WKN: A41BR2 | Symbol: PTHS]

Realtimekurs

Channel Therapeutics Corp. is a clinical-stage biotech company that engages in the development and commercialization of new therapeutics to alleviate pain. The company was founded in 2002 and is headquartered in Freehold, NJ.

10J

Alles

Vorbörsliche Indikationen

Regulärer Handel

Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Es konnten keine Nachrichten über Pelthos Therapeutics gefunden werden.

Pelthos Therapeutics Nachrichtenticker öffnen

MT Newswires 14.08.2026 14:43 Uhr

--Oppenheimer passt Kursziel für Pelthos Therapeutics von $66 auf $64 an, behält Outperform-Rating bei

MT Newswires 30.06.2026 23:37 Uhr

Pelthos Therapeutics in Russell 3000E Growth- und Microcap-Indizes aufgenommen

05:36 PM EDT, 06/30/2026 (MT Newswires) -- Pelthos Therapeutics (PTHS) wurde am Montag in den Russell 3000E Growth Benchmark, den Russell Microcap Ind